Hey there Sage,
I know active traders see dozens of reverse mergers hit the BOB every week.
AEPP is different than all of the ones I have seen over the years.
Most OTC reverse mergers are heavily diluted with large share structures.
AEPP is unique because of the small float and O/S, which gives us the small market cap that investors like to see.
Most OTC reverse mergers don’t have accredited investors already onboard.
Oncolix is unique because they have a proven history of being able to raise investment capital as a private company.
Most OTC reverse mergers don’t include companies with a significant worldwide patent portfolio like Oncolix has.
For me, AEPP is an OTC hat trick for investors that can recognize the difference between the risk/reward ratio of AEPP vs. every other reverse merger currently in play.
10,000 shares of AEPP @ .08 = $800. As with any other OTC play, you could lose it all. Thats the risk.
An Oncolix/AEPP with a $93 market cap, post merger, is possible with everything that is currently known.
A $93M market cap would give AEPP a PPS of $1.00.
10,000 shares @ $1.00 = $10,000.
Potential risk = $800 for a potential reward of $10,000.
I like those odds.
IMO and FWIW.
Market Data 
Markets 
AI
